Polyphor AG bags funding for murepavadin
Polyphor has secured $3.3m from the Cystic Fibrosis Foundation as support for clinical Phase I/IIa testing of its inhaled antibiotic murepavadin.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1123 entries already.
Entries by Thomas Gabrielczyk
EU COVID-19 antibody ready for clinical trials
/in News/by Thomas GabrielczykAs investments into COVID-19 therapeutics is no EU priority, development is lagging behind the US. Now, CORAT Therapeutics candidate COR101 is set to enter clinical testing.
COVID-19: Moderna reports promising interim results
/in News/by Thomas GabrielczykAfter BioNTech SE reported that its COVID-19 vaccine candidate BNT162b2 was over 90% efficient in a Phase III trial, Moderna Inc announced an efficacy of 94.5%.
BioNTech reports high efficacy of COVID-19 vaccine
/in News/by Thomas GabrielczykInterim data on BioNtechs/Pfizers COVID-19 vaccine candidate BNT162b2 suggest an efficacy of more than 90% – 30% better than required by the FDA.
Vifor Pharma inks $340m deal with Angion Biomedica Inc.
/in News/by Thomas GabrielczykSwiss drugmaker Vifor Pharma has licenced US and EU commercialisation rights of Angion Biomedicas experimental kidney drug ANG-3777.
Cell and gene therapy specialist Minaris expanding
/in News/by Thomas GabrielczykJapanese CDMO Minaris Regenerative Medicine Co. Ltd will invest US$64.5m to expand its facilities in Europe and Asia.
Protein Brewery raise 22m in Series A
/in News/by Thomas GabrielczykLead investor Novo Growth has led a 22m Series A investment in The Protein Brewery, a Dutch company that is to supplement the market for protein alternatives by fungal protein.
Galecto raise US$85m in Nasdaq IPO
/in News/by Thomas GabrielczykHBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq.
BI initiates Phase II testing of COVID-19 drug
/in News/by Thomas GabrielczykBoehringer Ingelheim announced the start of Phase II studies of its oral TRPC6 blocker code-named BI 764198 in patients hospitalised for COVID-19.
3P Bio to manufacture SpyBiotech vaccine
/in News/by Thomas GabrielczykBritish SpyBiotech has outsourced GMP manufacturing of its VLP vaccine platform to Navarra-based 3P Biopharmaceuticals.